Research | Core Facilities | Patient Studies | Tech Transfer | Seminars | Intranet | Jobs | Search | Contact Us | Ways To Give HOME
|
|
|
|
|
|
|||
|
Research | Core Facilities | Patient Studies | Tech Transfer | Seminars | Intranet | Jobs | Search | Contact Us | Ways To Give HOME |
|||
 |
|||
|
Experimental Therapeutics Research Program |
OMRF’s Experimental Therapeutics Research Program, under the direction of Robert A. Floyd, Ph.D., focuses on new discoveries in biomedical research and their role in the development of novel therapeutic approaches for treating important human diseases. At this critical interface, which is often underserved in the biomedical research arena, researchers can pose creative new scientific questions and conduct experiments to evaluate if novel therapeutics can arise. With over 20 years of experience working in both basic biomedical science and the development of novel therapeutics, the scientists in this program have helped to develop agents to effectively photo-inactivate important RNA viruses, including HIV and West Nile viruses. Their research also has led to the discovery that nitrones are effective in preventing brain damage caused by stroke in experimental animals. As a result of these discoveries, specific nitrones underwent 12 years of commercial development—leading to Phase III clinical trials—for the treatment of stroke. Current research projects focus on specific nitrones for the treatment of cancers and the mechanistic basis of their anti-cancer activity. Specifically, these experiments center on developing novel therapeutics for cancers, including glioblastoma and pancreatic cancer, where no effective therapeutics now exist. For more information, please contact: Robert A. Floyd, Ph.D., Program Head
|
||
